L L Houston

Title: L L Houston: A Pioneer in Biosynthetic Binding Proteins for Cancer Marker

Introduction:

L L Houston, based in Oakland, CA, is a highly accomplished inventor and researcher in the field of biosynthetic binding proteins. With an incredible portfolio of 10 patents to his name, Houston has made significant contributions to the development of technologies for cancer marker detection and immuno-targeting therapies. This article explores his latest patents, career highlights, notable collaborations, and the impact of his work in the field.

Latest Patents:

Houston's recent patents showcase his expertise in developing innovative solutions for cancer marker detection and immuno-targeting therapies. One of his notable inventions is the DNA encoding biosynthetic binding protein for cancer marker. This patent presents a breakthrough approach using a single-chain Fv (sFv) polypeptide that exhibits the immunological binding properties of an immunoglobulin molecule. The sFv polypeptide effectively binds to c-erbB-2 or a c-erbB-2-related tumor antigen, enabling accurate cancer marker identification.

Another valuable patent by Houston focuses on biosynthetic binding proteins for immuno-targeting. This formulation targets specific epitopes on antigens expressed in mammals. The dimeric biosynthetic construct contained in this patent consists of two polypeptide chains with C-terminal tails, facilitating the crosslinking of two sFv polypeptides. This construct enables efficient binding of preselected antigens, making it an excellent tool for drug targeting experiments and in vivo imaging.

Career Highlights:

Throughout his career, Houston has made significant contributions to the field of biosynthetic binding proteins.His work in companies such as Chiron Corporation and Cetus Corporation has solidified his reputation as a key figure in the industry. His advancements in cancer marker detection and immuno-targeting therapies have paved the way for groundbreaking diagnostic and treatment options, improving the lives of patients worldwide.

Collaborations:

L L Houston has had the privilege of collaborating with renowned experts in the field. Notably, he has worked alongside James S Huston and David B Ring, both accomplished individuals in biosynthetic binding protein research. These collaborations have fostered an environment of knowledge sharing, further propelling their collective efforts in developing revolutionary technologies.

Conclusion:

L L Houston's remarkable career in the development of biosynthetic binding proteins for cancer marker detection and immuno-targeting therapies underscores his influential role in the field. Through his numerous patents and collaborations, he has made significant contributions that will continue to shape the landscape of cancer diagnostics and therapeutics. Houston's dedication to innovation and his work's impact on improving patient outcomes make him a distinguished figure in the realm of biosynthetic binding proteins.